-
Innovation Ranking
NewInnovation Ranking – Werner Enterprises Inc
Werner Enterprises Inc (Werner) is a provider of transportation and logistics services. The company offers various truckload transportation services such as dedicated; medium-to-long-haul, the regional short haul; expedited; temperature-controlled; and flatbed services. It offers logistics services include freight management, final mile, truck brokerage, intermodal and international services. Werner offers customs brokerage, equipment leasing, and third-party equipment maintenance services. The company serves retail store merchandise, consumer products, food and beverage products, manufacturing, and distribution industries. The company, through its subsidiaries, has...
-
Product Insights
Werner Syndrome ATP Dependent Helicase – Drugs In Development, 2023
Global Markets Direct’s Werner Syndrome ATP Dependent Helicase provides in depth analysis on Werner Syndrome ATP Dependent Helicase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Werner...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6457 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6457 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6457 in Solid Tumor Drug Details: RG-6457 (RO-7589831) is under development...
-
Company Insights
Innovation and Patenting activity of Werner Enterprises Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Werner Enterprises Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGS-2 in Werner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGS-2 in Werner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRGS-2 in Werner SyndromeDrug Details:PRG-S-2 is under development for treatment of Werner Syndrome.Report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGS-1 in Werner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGS-1 in Werner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRGS-1 in Werner SyndromeDrug Details:PRGS-1 (progerinin) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRO-761 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRO-761 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HRO-761 in Solid Tumor Drug Details: HRO-761 is under development for...
-
Company Insights
BAM Nuttall Ltd – Digital Transformation Strategies
BAM Nuttall Ltd Digital Transformation Strategies Overview BAM Nuttall Ltd. (BAM Nuttall) is a civil engineering company offering design and construction services using several disruptive digital technologies, including building information modelling (BIM), augmented reality (AR), and robotics to improve the buildability, sustainability, and safety of its construction projects. The annual ICT spending of BAM Nuttall was estimated at $15.25 million in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. BAM...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRX-3140 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRX-3140 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRX-3140 in Alzheimer's Disease Drug Details:PRX-03140 (NTC-942) is under development for the treatment of Alzheimer's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GD2-SADA in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GD2-SADA in Small-Cell Lung Cancer Drug Details:Monoclonal antibody conjugate is under development for the treatment of...